NCT01878799View on ClinicalTrials.gov

Study of A Combination Pill With GS-7977 and GS-5885 for Hepatitis C in People With HIV

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions
Hepatitis CHIV
Interventions
DRUG

GS-7977/GS- 5885 FDC

The GS-7977/GS-5885 FDC product combines a potent HCV nucleotide inhibitor and a potent HCV NS5A inhibitor and will be given for 12 weeks.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT01878799 - Study of A Combination Pill With GS-7977 and GS-5885 for Hepatitis C in People With HIV | Biotech Hunter | Biotech Hunter